Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities (2021 - 2026)

Journey Medical filings provide 5 years of Cash from Financing Activities readings, the most recent being $5.4 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 48.9% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.2 million, a 4.51% decrease, with the full-year FY2025 number at $16.2 million, down 4.51% from a year prior.
  • Cash from Financing Activities hit $5.4 million in Q4 2025 for Journey Medical, down from $7.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $31.8 million in Q4 2021 to a low of -$13.1 million in Q2 2023.
  • Median Cash from Financing Activities over the past 5 years was $3.8 million (2022), compared with a mean of $4.9 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 11890.99% in 2023 and later surged 3048.08% in 2024.
  • Journey Medical's Cash from Financing Activities stood at $31.8 million in 2021, then tumbled by 97.02% to $948000.0 in 2022, then surged by 1926.37% to $19.2 million in 2023, then tumbled by 44.72% to $10.6 million in 2024, then tumbled by 48.9% to $5.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $5.4 million (Q4 2025), $7.0 million (Q3 2025), and $165000.0 (Q2 2025) per Business Quant data.